<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060550</url>
  </required_header>
  <id_info>
    <org_study_id>ML41620</org_study_id>
    <nct_id>NCT04060550</nct_id>
  </id_info>
  <brief_title>Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum</brief_title>
  <official_title>Investigate the Impact of Increased IgE on Innate Anti-herpes Simplex Virus 1 Responses in the Eczema Herpeticum Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether blood monocytes' surface bound- immunoglobulin E affects the&#xD;
      innate immune responses against herpes simplex viruses in atopic dermatitis patients with&#xD;
      eczema herpeticum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some of atopic dermatitis patients (AD) have severe herpes simplex viral (HSV) infections,&#xD;
      which could cause erosive skin lesions all over the body. This condition is termed as eczema&#xD;
      herpeticum (ADEH+). Scientists have found that ADEH+ patients have significantly increased&#xD;
      blood immunoglobulin (Ig) E compared to AD patients without eczema herpeticum and healthy&#xD;
      people. Increased IgE in blood could bound to immune cells' surface, such as monocytes. Since&#xD;
      monocytes serve as the first line defense to fight viral infection, their surface-bound IgE&#xD;
      may interfere their anti-viral immune responses, and consequently results in more severe&#xD;
      viral infections. The purpose of this study is to learn more about how increased IgE affect&#xD;
      body's immune ability to fight herpes simplex viruses. This study includes three groups: AD&#xD;
      patient without eczema herpeticum complication(ADEH-); AD patient with eczema herpeticum&#xD;
      complication(ADEH+) and healthy controls. Study results will be compared between groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Monocytes surface bound IgE quantities</measure>
    <time_frame>One day</time_frame>
    <description>Relative quantities of surface bound IgE</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Atopic Dermatitis With a History of Eczema Herpeticum</condition>
  <condition>Atopic Dermatitis Without a History of Eczema Herpeticum</condition>
  <condition>Health Controls Without Atopy</condition>
  <arm_group>
    <arm_group_label>Normal controls</arm_group_label>
    <description>No history of skin disease and atopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADEH-</arm_group_label>
    <description>Atopic dermatitis without a history of eczema herpeticum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADEH+</arm_group_label>
    <description>Atopic dermatitis with a history of eczema herpeticum</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Xolair</intervention_name>
    <description>This is in vitro mechanistic study. No drug will be given in vivo to patients.</description>
    <arm_group_label>ADEH+</arm_group_label>
    <arm_group_label>ADEH-</arm_group_label>
    <arm_group_label>Normal controls</arm_group_label>
    <other_name>omalizumab</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood, monocytes purified from peripheral blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        One of the following groups:&#xD;
&#xD;
          1. A history of AD with a history of eczema herpeticum, ADEH+, as diagnosed using the&#xD;
             Atopic Dermatitis Research Network Standard Diagnostic Criteria.&#xD;
&#xD;
          2. A history of AD without a history of eczema herpeticum, ADEH-, as diagnosed using&#xD;
             Atopic Dermatitis Research Network Standard Diagnostic Criteria, and no first degree&#xD;
             relatives with a history of EH.&#xD;
&#xD;
          3. Non-atopic as diagnosed using Atopic Dermatitis Research Network Standard Diagnostic&#xD;
             Criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 16-65 years old, age, sex and race match among non-atopic, ADEH- and ADEH+.&#xD;
&#xD;
          -  Participant and/or parent guardian must be able to understand and provide informed&#xD;
             consent, and fits in one of the following conditions:&#xD;
&#xD;
               1. A history of AD with a history of eczema herpeticum, ADEH+, as diagnosed using&#xD;
                  the Atopic Dermatitis Research Network Standard Diagnostic Criteria.&#xD;
&#xD;
               2. A history of AD without a history of eczema herpeticum, ADEH-, as diagnosed using&#xD;
                  Atopic Dermatitis Research Network Standard Diagnostic Criteria, and no first&#xD;
                  degree relatives with a history of EH.&#xD;
&#xD;
               3. Non-atopic as diagnosed using Atopic Dermatitis Research Network Standard&#xD;
                  Diagnostic Criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability or unwillingness of a participant to give written informed consent or comply&#xD;
             with study protocol&#xD;
&#xD;
          -  Known or suspected immunosuppression&#xD;
&#xD;
          -  Severe concomitant illness(es)&#xD;
&#xD;
          -  Women of childbearing potential not using the contraception method(s) specified in&#xD;
             this study (specify), as well as women who are breastfeeding&#xD;
&#xD;
          -  Known sensitivity to study drug(s) or class of study drug(s)&#xD;
&#xD;
          -  Patients with severe medical condition(s) that in the view of the investigator&#xD;
             prohibits participation in the study (specify as required)&#xD;
&#xD;
          -  Use of any other investigational agent in the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lianghua Bin, MD&amp;PhD</last_name>
    <phone>3032702055</phone>
    <email>binl@njhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donald Leung, MD&amp;PhD</last_name>
    <phone>3033981886</phone>
    <email>leungd@njhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Taylor, NP-C</last_name>
      <phone>303-398-1067</phone>
      <phone_ext>1067</phone_ext>
      <email>taylorp@njhealth.org</email>
    </contact>
    <investigator>
      <last_name>Lianghua Bin, MD &amp; PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donald Leung, MD &amp; PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Eczema herpeticum</keyword>
  <keyword>Immunoglobulin E</keyword>
  <keyword>Herpes simplex virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Kaposi Varicelliform Eruption</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

